The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Diabetic Gastroparesis-Global Market Insights and Sales Trends 2024
Synopsis
Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the vagus nerve, in cases where the blood glucose levels remain high over a longer duration. Diabetes gastroparesis is usually diagnosed with the help of imaging techniques such as ultrasound and x-ray, which is accompanied by the intake of radio isotopic meals containing barium, or using hematological / blood tests, and endoscopic techniques. There has been a marked increase in the prevalence of diabetes, especially in the developing countries, including China, India, Brazil, and some other Asian countries, leading to increasing incidence of diabetic neuropathy and consequent rise in diabetes gastroparesis around the world.
The global Diabetic Gastroparesis market size is expected to reach US$ 3010.2 million by 2029, growing at a CAGR of 5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Diabetic Gastroparesis in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Diabetic Gastroparesis market. Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgical Treatment Products segment is estimated at % CAGR for the next seven-year period.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Diabetic Gastroparesis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Diabetic Gastroparesis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Diabetic Gastroparesis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Diabetic Gastroparesis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Diabetic Gastroparesis covered in this report include Medtronic, Sumitomo Dainippon Pharma, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services, LLC, Alfasigma SpA, Evoke Pharma and Cadila Pharmaceuticals, etc.
The global Diabetic Gastroparesis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Medtronic
Sumitomo Dainippon Pharma
Abbott Laboratories
Boston Scientific Corporation
C. R. Bard, Inc
Janssen Global Services, LLC
Alfasigma SpA
Evoke Pharma
Cadila Pharmaceuticals
Sanofi
Teva Pharmaceutical Industries Ltd
Pfizer
Vanda Pharmaceuticals
Allergan
Global Diabetic Gastroparesis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Diabetic Gastroparesis market, Segment by Type:
Drugs
Surgical Treatment Products
Global Diabetic Gastroparesis market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Diabetic Gastroparesis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the vagus nerve, in cases where the blood glucose levels remain high over a longer duration. Diabetes gastroparesis is usually diagnosed with the help of imaging techniques such as ultrasound and x-ray, which is accompanied by the intake of radio isotopic meals containing barium, or using hematological / blood tests, and endoscopic techniques. There has been a marked increase in the prevalence of diabetes, especially in the developing countries, including China, India, Brazil, and some other Asian countries, leading to increasing incidence of diabetic neuropathy and consequent rise in diabetes gastroparesis around the world.
The global Diabetic Gastroparesis market size is expected to reach US$ 3010.2 million by 2029, growing at a CAGR of 5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Diabetic Gastroparesis in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Diabetic Gastroparesis market. Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgical Treatment Products segment is estimated at % CAGR for the next seven-year period.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Diabetic Gastroparesis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Diabetic Gastroparesis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Diabetic Gastroparesis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Diabetic Gastroparesis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Diabetic Gastroparesis covered in this report include Medtronic, Sumitomo Dainippon Pharma, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services, LLC, Alfasigma SpA, Evoke Pharma and Cadila Pharmaceuticals, etc.
The global Diabetic Gastroparesis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Medtronic
Sumitomo Dainippon Pharma
Abbott Laboratories
Boston Scientific Corporation
C. R. Bard, Inc
Janssen Global Services, LLC
Alfasigma SpA
Evoke Pharma
Cadila Pharmaceuticals
Sanofi
Teva Pharmaceutical Industries Ltd
Pfizer
Vanda Pharmaceuticals
Allergan
Global Diabetic Gastroparesis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Diabetic Gastroparesis market, Segment by Type:
Drugs
Surgical Treatment Products
Global Diabetic Gastroparesis market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Diabetic Gastroparesis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Diabetic Gastroparesis
1.1 Diabetic Gastroparesis Market Overview
1.1.1 Diabetic Gastroparesis Product Scope
1.1.2 Diabetic Gastroparesis Market Status and Outlook
1.2 Global Diabetic Gastroparesis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Diabetic Gastroparesis Market Size by Region (2018-2029)
1.4 Global Diabetic Gastroparesis Historic Market Size by Region (2018-2023)
1.5 Global Diabetic Gastroparesis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Diabetic Gastroparesis Market Size (2018-2029)
1.6.1 North America Diabetic Gastroparesis Market Size (2018-2029)
1.6.2 Europe Diabetic Gastroparesis Market Size (2018-2029)
1.6.3 Asia-Pacific Diabetic Gastroparesis Market Size (2018-2029)
1.6.4 Latin America Diabetic Gastroparesis Market Size (2018-2029)
1.6.5 Middle East & Africa Diabetic Gastroparesis Market Size (2018-2029)
2 Diabetic Gastroparesis Market by Type
2.1 Introduction
2.1.1 Drugs
2.1.2 Surgical Treatment Products
2.2 Global Diabetic Gastroparesis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Diabetic Gastroparesis Historic Market Size by Type (2018-2023)
2.2.2 Global Diabetic Gastroparesis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Diabetic Gastroparesis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Diabetic Gastroparesis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Diabetic Gastroparesis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Diabetic Gastroparesis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Diabetic Gastroparesis Revenue Breakdown by Type (2018-2029)
3 Diabetic Gastroparesis Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Diabetic Gastroparesis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Diabetic Gastroparesis Historic Market Size by Application (2018-2023)
3.2.2 Global Diabetic Gastroparesis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Diabetic Gastroparesis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Diabetic Gastroparesis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Diabetic Gastroparesis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Diabetic Gastroparesis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Diabetic Gastroparesis Revenue Breakdown by Application (2018-2029)
4 Diabetic Gastroparesis Competition Analysis by Players
4.1 Global Diabetic Gastroparesis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Diabetic Gastroparesis as of 2022)
4.3 Date of Key Players Enter into Diabetic Gastroparesis Market
4.4 Global Top Players Diabetic Gastroparesis Headquarters and Area Served
4.5 Key Players Diabetic Gastroparesis Product Solution and Service
4.6 Competitive Status
4.6.1 Diabetic Gastroparesis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Medtronic
5.1.1 Medtronic Profile
5.1.2 Medtronic Main Business
5.1.3 Medtronic Diabetic Gastroparesis Products, Services and Solutions
5.1.4 Medtronic Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.1.5 Medtronic Recent Developments
5.2 Sumitomo Dainippon Pharma
5.2.1 Sumitomo Dainippon Pharma Profile
5.2.2 Sumitomo Dainippon Pharma Main Business
5.2.3 Sumitomo Dainippon Pharma Diabetic Gastroparesis Products, Services and Solutions
5.2.4 Sumitomo Dainippon Pharma Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.2.5 Sumitomo Dainippon Pharma Recent Developments
5.3 Abbott Laboratories
5.3.1 Abbott Laboratories Profile
5.3.2 Abbott Laboratories Main Business
5.3.3 Abbott Laboratories Diabetic Gastroparesis Products, Services and Solutions
5.3.4 Abbott Laboratories Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.3.5 Boston Scientific Corporation Recent Developments
5.4 Boston Scientific Corporation
5.4.1 Boston Scientific Corporation Profile
5.4.2 Boston Scientific Corporation Main Business
5.4.3 Boston Scientific Corporation Diabetic Gastroparesis Products, Services and Solutions
5.4.4 Boston Scientific Corporation Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.4.5 Boston Scientific Corporation Recent Developments
5.5 C. R. Bard, Inc
5.5.1 C. R. Bard, Inc Profile
5.5.2 C. R. Bard, Inc Main Business
5.5.3 C. R. Bard, Inc Diabetic Gastroparesis Products, Services and Solutions
5.5.4 C. R. Bard, Inc Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.5.5 C. R. Bard, Inc Recent Developments
5.6 Janssen Global Services, LLC
5.6.1 Janssen Global Services, LLC Profile
5.6.2 Janssen Global Services, LLC Main Business
5.6.3 Janssen Global Services, LLC Diabetic Gastroparesis Products, Services and Solutions
5.6.4 Janssen Global Services, LLC Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.6.5 Janssen Global Services, LLC Recent Developments
5.7 Alfasigma SpA
5.7.1 Alfasigma SpA Profile
5.7.2 Alfasigma SpA Main Business
5.7.3 Alfasigma SpA Diabetic Gastroparesis Products, Services and Solutions
5.7.4 Alfasigma SpA Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.7.5 Alfasigma SpA Recent Developments
5.8 Evoke Pharma
5.8.1 Evoke Pharma Profile
5.8.2 Evoke Pharma Main Business
5.8.3 Evoke Pharma Diabetic Gastroparesis Products, Services and Solutions
5.8.4 Evoke Pharma Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.8.5 Evoke Pharma Recent Developments
5.9 Cadila Pharmaceuticals
5.9.1 Cadila Pharmaceuticals Profile
5.9.2 Cadila Pharmaceuticals Main Business
5.9.3 Cadila Pharmaceuticals Diabetic Gastroparesis Products, Services and Solutions
5.9.4 Cadila Pharmaceuticals Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.9.5 Cadila Pharmaceuticals Recent Developments
5.10 Sanofi
5.10.1 Sanofi Profile
5.10.2 Sanofi Main Business
5.10.3 Sanofi Diabetic Gastroparesis Products, Services and Solutions
5.10.4 Sanofi Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.10.5 Sanofi Recent Developments
5.11 Teva Pharmaceutical Industries Ltd
5.11.1 Teva Pharmaceutical Industries Ltd Profile
5.11.2 Teva Pharmaceutical Industries Ltd Main Business
5.11.3 Teva Pharmaceutical Industries Ltd Diabetic Gastroparesis Products, Services and Solutions
5.11.4 Teva Pharmaceutical Industries Ltd Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.11.5 Teva Pharmaceutical Industries Ltd Recent Developments
5.12 Pfizer
5.12.1 Pfizer Profile
5.12.2 Pfizer Main Business
5.12.3 Pfizer Diabetic Gastroparesis Products, Services and Solutions
5.12.4 Pfizer Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.12.5 Pfizer Recent Developments
5.13 Vanda Pharmaceuticals
5.13.1 Vanda Pharmaceuticals Profile
5.13.2 Vanda Pharmaceuticals Main Business
5.13.3 Vanda Pharmaceuticals Diabetic Gastroparesis Products, Services and Solutions
5.13.4 Vanda Pharmaceuticals Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.13.5 Vanda Pharmaceuticals Recent Developments
5.14 Allergan
5.14.1 Allergan Profile
5.14.2 Allergan Main Business
5.14.3 Allergan Diabetic Gastroparesis Products, Services and Solutions
5.14.4 Allergan Diabetic Gastroparesis Revenue (US$ Million) & (2018-2023)
5.14.5 Allergan Recent Developments
6 North America
6.1 North America Diabetic Gastroparesis Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Diabetic Gastroparesis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Gastroparesis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Diabetic Gastroparesis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Gastroparesis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Diabetic Gastroparesis Market Dynamics
11.1 Diabetic Gastroparesis Industry Trends
11.2 Diabetic Gastroparesis Market Drivers
11.3 Diabetic Gastroparesis Market Challenges
11.4 Diabetic Gastroparesis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
